Latest Market Disclosures News

Yowie Group has appointed Jesse Hamilton as its new Company Secretary, following the resignation of John Patton. The company also confirmed the automatic termination of executive roles held by former directors Nicholas Bolton and John Patton.

Pure Hydrogen Corporation has confirmed that the delivery and formal acceptance of its Taurus Hydrogen Fuel Cell Prime Mover to Barwon Water is material information likely to affect its share price, responding to ASX queries on disclosure timing and compliance.

Bowen Coking Coal has announced it will remain suspended on the ASX as it reassesses its operational plans and explores financing options amid challenging market conditions.

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

OFX Group Limited has responded to ASX concerns over its FY25 earnings disclosure, confirming earnings below consensus but no breach of continuous disclosure rules.

Axel REE Limited has responded to ASX Compliance queries confirming the timely disclosure of its latest rare earth element drilling results at the Poços de Caldas Caldera, emphasizing the incremental nature of the findings and ongoing compliance with listing rules.

Nufarm Limited confirms its half-year earnings align closely with analyst expectations despite a late-stage $16 million inventory valuation adjustment. The company maintains compliance with ASX disclosure rules amid market scrutiny.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Alvo Minerals has voluntarily suspended trading of its shares on the ASX as it finalizes an Entitlement Offer and prepares to announce progress on the Lavra Velha Project acquisition.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.

Insignia Financial updates the market on its acquisition talks, revealing Bain Capital's withdrawal due to global market volatility while discussions with CC Capital continue without certainty.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.